StreetInsider.com News Articles

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act.

The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockbuster tirzepatide drugs, Zepbound and Mounjaro. Novo Nordisk claims the ads are false and misleading because they

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk sues Eli Lilly over weight-loss drug ads

Tue, 21 Jul 2026 07:36:27 -0400

Investing.com -- Novo Nordisk filed a lawsuit on Tuesday against Eli Lilly in U.S. District Court in New Jersey, claiming the American pharmaceutical company engaged in false advertising by stating its weight-loss medications perform better than Novo's products.

The Danish drugmaker said the lawsuit alleges Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.

According to Novo, Lilly compared the highest approved doses of its medications with lower doses of Novo's Wegovy and Ozempic while leaving out newer, higher-dose versions that Novo says produce

Novo Nordisk sues Eli Lilly over weight-loss drug ads

Tue, 21 Jul 2026 07:36:27 -0400

According to Novo, Lilly compared the highest approved doses of its medications with lower doses of Novo's Wegovy and Ozempic while leaving out newer, higher-dose versions that Novo says produce

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

The analyst comments "Downgrading to Neutral following agreement to be acquired by Eli Lilly; lowering our price target to $7.50 from $25. On July 16, AtaiBeckley announced that it entered into a definitive agreement to be acquired by Eli Lilly (LLY; not rated) in a transaction valued at up to approximately $3.8 billion. Lilly will acquire all outstanding AtaiBeckley shares for $6.75 per share in cash upon closing, plus a contingent value right (CVR)

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

UBS Reiterates Buy Rating on Eli Lilly (LLY) on Deal to Acquire ATAI

Fri, 17 Jul 2026 09:13:14 -0400

UBS analyst Michael Yee reiterated a Buy rating and $1,425.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented, "Eli Lilly announced it will acquire ATAI (AtaiBeckley) for ~$2.8B upfront, and up to $1B in CVR. Strategically, the acquisition aligns and actually coincides with Dave Ricks comments on an investor podcast a few weeks ago in which he believes neuropsych can be an area of development that could have the best chance of "competing with the cardiometabolic" portfolio ie because big TAM and underpenetrated markets. Today's deal gives LLY the optionality to play in this market with a Phase III

Oppenheimer on AtaiBeckley Inc (ATAI): 'LLY Acquisition Validates Psychedelic Advantages'

Thu, 16 Jul 2026 10:00:57 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $16.00 price target on AtaiBeckley Inc (NASDAQ: ATAI).

The analyst comments "We view LLY's acquisition of ATAI for ~$3.8B total equity value as validating our conviction in the transformative potential of psychedelic medicine. We see unique advantages for the shorter-acting MOAs of BPL-003 (5-MeO-DMT) and VLS-01, for which we imagine operational synergies for a large pharma that could most readily leverage commercial infrastructure to accelerate uptake. Deal terms include ~$2.8B upfront reflecting a $6.75/share value plus ~$1B in CVRs including: 1) $1.00/share upon initiating a Ph3 study for VLS-01 within 4 years

Oppenheimer on AtaiBeckley Inc (ATAI): 'LLY Acquisition Validates Psychedelic Advantages'

Thu, 16 Jul 2026 10:00:57 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $16.00 price target on AtaiBeckley Inc (NASDAQ: ATAI).

Eli Lilly to acquire AtaiBeckley for up to $3.8B